Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment

Elyse R Park; Jordan M Neil; Elise Noonan; Sydney E Howard; Irina Gonzalez; Caylin Marotta; Amy J Wint; Douglas E Levy; Yuchiao Chang; Nancy A Rigotti; Jennifer S Haas

doi:10.1093/jncics/pkac073

Leveraging the Clinical Timepoints in Lung Cancer Screening to Engage Individuals in Tobacco Treatment

JNCI Cancer Spectr. 2022 Nov 1;6(6):pkac073. doi: 10.1093/jncics/pkac073.

Authors

Elyse R Park^{1

2

3

4}, Jordan M Neil^{1

5

6}, Elise Noonan^{1

2}, Sydney E Howard⁷, Irina Gonzalez^{1

2}, Caylin Marotta⁷, Amy J Wint⁷, Douglas E Levy^{2

3}, Yuchiao Chang^{3

7}, Nancy A Rigotti^{2

3

7}, Jennifer S Haas^{2

7}

Affiliations

¹ Health Promotion and Resiliency and Intervention Research Program, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Mongan Institue, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Tobacco Research and Treatment Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
⁶ TSET Health Promotion Research Center, Stephenson Cancer Center, Oklahoma City, OK, USA.
⁷ Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

The US Preventive Services Task Force recommends lung cancer screening (LCS) to promote early lung cancer detection, and tobacco cessation services are strongly recommended in adjunct. Screen ASSIST (NCT03611881) is a randomized factorial trial to ascertain the best tobacco treatment intervention for smokers undergoing LCS; trial outreach is conducted during 3 recruitment points (RPs): when LCS is ordered (RP1), at screening (RP2), and following results (RP3). Among 177 enrollees enrolled from April 2019 to March 2020, 31.6% enrolled at RP1, 13.0% at RP2, and 55.4% at RP3. The average number of enrollees (per 1000 recruitment days) was 2.26 in RP1, 3.37 in RP2, and 1.04 in RP3. LCS provides an opportunity to offer tobacco treatment at multiple clinical timepoints. Repeated and proactive outreach throughout the LCS experience was beneficial to enrolling patients in tobacco cessation services.

Publication types

Randomized Controlled Trial
Research Support, N.I.H., Extramural

MeSH terms

Early Detection of Cancer
Humans
Lung Neoplasms* / diagnosis
Nicotiana
Smoking Cessation* / methods
Tobacco Use Cessation*

Associated data

ClinicalTrials.gov/NCT03611881

Grants and funding

R01 CA218123/CA/NCI NIH HHS/United States